INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $256,273 | +10.6% | 4,918 | +34.4% | 0.00% | – |
| Q2 2023 | $231,688 | +10.5% | 3,659 | -7.5% | 0.00% | – |
| Q4 2022 | $209,734 | -27.7% | 3,954 | -56.5% | 0.00% | – |
| Q4 2020 | $290,000 | -5.2% | 9,088 | -23.9% | 0.00% | -100.0% |
| Q2 2020 | $306,000 | +11.7% | 11,940 | -67.4% | 0.00% | 0.0% |
| Q3 2019 | $274,000 | -73.9% | 36,654 | -24.2% | 0.00% | -50.0% |
| Q3 2018 | $1,049,000 | +414.2% | 48,357 | +318.1% | 0.00% | – |
| Q2 2018 | $204,000 | -89.8% | 11,566 | -87.8% | 0.00% | -100.0% |
| Q1 2018 | $1,996,000 | +1132.1% | 94,808 | +783.1% | 0.00% | – |
| Q4 2016 | $162,000 | – | 10,736 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |